Anaveon is a biopharmaceutical company that transforms engineered cytokines into novel life-saving treatments. The first program going into clinical trials is a selective IL-2 receptor agonist.
Location: Switzerland, Basel-City, Basel
Total raised: $119.73M
Investors 3
| Date | Name | Website |
| 22.03.2022 | Forbion | forbion.co... |
| 18.11.2023 | Syncona Pa... | synconaltd... |
| - | Pontifax V... | pontifax.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.12.2021 | Series B | $119.73M | - |
Mentions in press and media 13
| Date | Title | Description |
| 08.04.2026 | Swiss startups appoint new CEOs and senior hires across biotech, AI and proptech | Anaveon, a pre-clinical biotechnology company developing immune-modulating therapies for autoimmune and inflammatory disorders, has appointed Thaminda Ramanayake as Chief Executive Officer. Ramanayake succeeds Andreas Katopodis, who led th... |
| 06.01.2025 | Executive reshuffle in four startups | As of this year, Ulrich Harmuth is the Chief Executive Officer at betterview, which has since its inception in 2021 established itself as the market leader in refractive surgery. The company has performed over 15,000 successful treatments.... |
| 02.08.2024 | Seasoned chairpersons and board members back life sciences startups | Anaveon, a clinical-stage company specializing in developing treatments for diseases with immune system dysfunction, focusing on biologics that modulate cytokine functions to provide therapeutic benefit has appointed former Chair and CEO o... |
| 11.06.2024 | Biotech startups make clinical progress | The U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application from Anaveon to conduct a Phase I/II study evaluating the safety and clinical activity of their drug candidate ANV600. As the company’s... |
| 19.09.2022 | Encouraging results for Anaveon’s lead molecule | |
| 17.12.2021 | Anaveon raises CHF 110 million to expand its phase II studies on an immuno-oncological agent and expand its cytokine engineering. | Anaveon raises CHF 110 million to expand its phase II studies on an immuno-oncological agent and expand its cytokine engineering. 17.12.2021 11:31, Guillaume Tinsel linkedIn facebook twitter instagram youtube --> Anaveon, a clinical-stag... |
| 16.12.2021 | Anaveon to raise CHF 110 million in oversubscribed Series B financing | - Leading international syndicate led by Forbion and corner-stoned by founding investor Syncona - Confirms depth of support for Anaveon’s approach to developing engineered cytokines in multiple indications BASEL, Switzerland, Dec. 16, 2021 ... |
| 16.12.2021 | Anaveon raises CHF 110 million | |
| 16.12.2021 | Anaveon to raise CHF 110 million in oversubscribed Series B financing | - Leading international syndicate led by Forbion and corner-stoned by founding investor Syncona - Confirms depth of support for Anaveon’s approach to developing engineered cytokines in multiple indications BASEL, Switzerland, Dec. 16, 2021 ... |
| 12.11.2021 | Anaveon announces poster presentation at the 2021 Society for Immunotherapy of Cancer Annual Meeting | ANV419 demonstrates highly promising safety profile November 12, 2021 - Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on its lead program ANV419 at the Society for Immunotherapy of Cancer'... |
Show more